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ABSTRACT. Economic analyses of geriatric syn-
dromes are seldom performed. However, demo-
graphic and epidemiological imperatives have led to
significant interest in the evaluation of AD-related
costs. Over 300 papers devoted to economic con-
siderations of Alzheimer’s disease have been pub-
lished in peer-reviewed journals, within the last
five years. In these papers, the chosen perspective
(costs to society or to specific payers) is impor-
tant. Analytical methods are still evolving and re-
main complex. Unresolved methodological issues
will need to be addressed to further our under-
standing of long-term economic consequences. At
present, it is clear that diagnostic and drug costs are
low compared to the major cost of institutional-
ization. Thus, directing efforts at early diagnosis
and delaying nursing home placement are two key
cost-containment interventions. In this respect,
the need to support informal care should not be un-
derestimated.
(Aging Clin. Exp. Res. 13: 255-260, 2001)
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“Dementia is certainly one of the most
dramatic medical and economic challenges
that our society will face in the coming
years”(1)
This strong statement by Souêtre recognizes the in-
teraction between world-wide demographic changes
and the particular nature of dementing conditions.
Population aging has resulted in a doubling of the
population over 60 years of age over the past century
in developed countries. This phenomenon is occur-
ring at accelerated rates in developing countries,
which will undergo a similar demographic change
over less than 3 decades (2). In most countries, the
prevalence of dementia varies between 6 and 8% for
individuals aged 65 years or more, and rises dra-
matically with age. For each decade after the 6th, the
number of affected people doubles so that an esti-
mated 30% of the 85+ population is affected by
dementia (3, 4). In a recent prevalence study per-
formed in Geneva, 5.6% of the population over the
age of 65 suffered from dementia; however, the
rate of the disease varied from 2.6% in women in the
65-70 years age group to 28.1% in men in the over
90 years group (5). In the United States, in 1994 de-
mentia ranked 9th in incidence (959,000 cases/year),
and 8th in prevalence (7,082,000 cases) (6). The
number of individuals with dementia will double be-
tween 1990 and 2005 in many developing countries,
such as Brazil, India, and Nigeria (7). These demo-
graphic and epidemiological considerations have
major economic consequences. Until a few years
ago, the economic impact of chronic conditions
such as dementia suffered a lack of theoretical and
empirical development (8). However, over 300 pa-
pers devoted to economic aspects of Alzheimer’s
disease (AD) have been published in peer reviewed
journals within the last five years. In these papers, the
chosen perspective (costs to society or to specific pay-
ers) is important to consider. The societal perspective
includes global costs, while that of specific payers
(e.g., patients, families, insurance companies, mu-
nicipality, county, etc.) may stress costs for which they
themselves are responsible (9).
COST OF THE ILLNESS FOR SOCIETY
The economic burden of dementia borne by society
includes all relevant costs regardless of the payers, and
is closely related to the rapidly increasing number of
demented patients (9, 10). Calculating such costs re-
quires complex analyses, however, some data are
available (9).
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In Switzerland, global dementia-related costs
reached $ 1.9 billion for 50,000 affected individuals
in 1998 (11). In the Netherlands, in 1994 dementia
ranked 3rd in total health care costs (5.6% of the total
budget, 7.4% for women and 2.9% for men), 1st in
the 65-84 years age group health care costs (9.5% of
the budget of this age group), and 1st in the over 85
years age group (22.2% of the health care costs)
(12). In the US, the annual direct costs of treating AD
were estimated to be $ 21.0 billion in 1991 (13), and
$ 29.8 billion in 1998 (14). This 42% difference is in-
dicative of the dramatic increases in health care costs
related to dementia. The US Health Care Finance Ad-
ministration has forecast an 80% increase in total
health care expenditures (to over $ 2 trillion annually)
between 1997 and 2007. The US government has
expressed significant concern that these costs could
threaten budgetary stability without any evidence of
pertinent outcomes or improvement in patients’ and
families’ quality of life (15). Although cost of illness
analyses can be crucial to direct social and health
policies, they do not provide information pertinent to
individual patients and carers.
COST ANALYSIS OF VARIOUS CARE
STRATEGIES OF DEMENTED PATIENTS
Cost perspectives from a specific payer’s point of
view (e.g., patients, families, insurance companies, mu-
nicipality, county, etc.) may include only selected
costs (9). Cost evaluations of various care strategies in-
clude “cost description” and “cost analysis”.
“Cost description” is an economic analysis that is
restricted to one type of treatment or care; it does not
include comparisons with alternative types of treatment
or care (16).
“Cost analysis” compares different therapies and
treatments, but does not compare their effects. A
large majority of economic studies of dementia care
are of this type, and many have their origin in local
projects or programs. Methodological strategies include
detailed cost analysis, average costs, longitudinal cost
analysis of patient care, and cost comparisons with
other types of care (10).
Both cost description and cost analysis include
costs linked to organizations operating within the
health sector. These costs can be distinguished in
direct and indirect costs.
Direct costs include:
- Direct medical costs: outpatient visits (general prac-
titioners, specialists, physical therapists, occupa-
tional therapists), laboratory investigations, diag-
nostic tests, drug costs, home care, social services
and hospitalization, as well as costs related to insti-
tutional care, which vary markedly within the same
country (depending on the staff number and com-
petence), and from one country to another (9, 16).
- Direct non-medical costs: rent for housing, light,
heat, food, out-of-pocket expenses, patient and
family involvement in care.
Indirect costs are essentially composed of:
- Medical costs linked to behavioral and psychiatric dis-
turbances, co-morbidities and drug side effects (17).
- Community costs including the loss of productivity as
a result of time lost from work.
- Intangible costs corresponding to psychological
consequences such as an AD patient’s pain and suf-
fering. These costs also include the family’s burden,
and are closely related to the nature of the family;
they have changed over time as a result of modifi-
cations in family composition, and the increasing
participation of women in the work force. Inter-gen-
eration patterns of informal care also need to be
considered when attempting to estimate intangi-
ble costs (18).
Methodological differences, lack of consensus con-
cerning the exact components of direct and indirect
costs, the difficulty inherent in the comparison of
different care systems, and differences between coun-
tries explain, in part, the discrepancies among in-
ternational cost evaluations. However, the important
impact of formal care on costs has been demon-
strated. In a recent comparison of dementia costs in
three different countries (19), the annual costs of illness
ranged from $ 52,000 (in the USA) to $ 23,600 (in
Sweden), and $ 6,000 (in England); these marked cost
variations were related to cross-national differences in
the ratio of formal to informal care which was 1/1 in
the USA, 1/2 in Sweden, and 1/6 in England.
- “Formal care” is defined either as care by a health
professional, or care by paid persons whatever their
competence. It is simpler to consider formal care as
an equivalent to “paid care” (20). The main com-
ponent of formal care is institutional care. In a
Swedish study of dementia, less than 1% of the na-
tional heath care system’s annual costs were de-
voted to diagnostic procedures, 1% to drugs, and an-
other 1% to day care; however, 67% of the yearly
costs were linked to institutional care (19).
- “Informal care” can then be considered as an equiv-
alent of “unpaid care”. In New York City, half of the
patients received informal care only (7.2 hours per
day), a quarter of them formal care only (9.8 hours
per day), and one third received both kinds of care
(14.6 hours per day) (21). There are two different
methods to evaluate informal costs. The first is the
“replacement cost method”, which values each in-
formal care hour at the equivalent hourly wage of a
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professional; the second method gauges the carer’s
cost in terms of having to give up paid employ-
ment, or to pass up the opportunity for career ad-
vancement (22).
Dementia-related costs vary during the course of the
illness.
At the early stage of the disease, direct costs,
linked to diagnostic consultations, neuropsychological
evaluations and testing procedures, are predominant
(1, 23). The time interval between the first symp-
toms and the first medical consultation is approxi-
mately 1.5-years (23). Currently, only 10 to 30% of
demented individuals are investigated. Thus, direct
costs related to this process should increase consid-
erably if all individuals with cognitive impairment
could benefit from a diagnostic evaluation (19).
It is important to note that each decrease of one
point in the MMSE score increases the annual de-
mentia costs by 4%. Moreover, costs are also related
to concomitant disease, behavioral disturbances and
psychiatric symptoms (21, 24). Thus, early intervention
has the potential to decrease disease-related costs.
In severely demented patients, non-medical costs,
linked to caring time spent by a third party (house-
work, custodial care…) or to institutionalization are
largely superior to medical costs (1). In Canada, in-
stitutionalization is the largest component of cost,
accounting for 84% of the cost for people with severe
dementia (25). In the USA, nursing home care rep-
resents 71% of US long-term care expenditures that
reached $ 90.9 billion in 1995 (26).
In a British cross-sectional study, non-institution-
alized patients with AD (N=128), their caregivers
(N=128), and 56 non-demented matched controls
were interviewed once to establish resource use. Over
a three-month period, the mean cost per control
subject (387 £) was less than that incurred by patients
with mild (6616 £), moderate (10,250 £) and se-
vere (13,593 £) AD. Indirect cost, mainly time spent
by caregivers, was the main cost component in all
groups (68.6%), followed by direct medical costs
(24.7%) (27).
TRADE-OFF ANALYSIS BETWEEN CARE
COSTS AND DEFINED/SUPPOSED
OUTCOMES
Previously described cost evaluations do not take in-
to account a care strategy’s results. Trade-off analysis,
on the contrary, also considers defined or assumed
outcomes; it includes cost-minimization, cost-benefit,
cost-effectiveness and cost-utility analyses. In its
strictest sense, pharmacoeconomics can also be in-
cluded among these types of analyses.
“Cost-minimization” analysis (CMA): Assuming
equivalent effects of two treatments or two care
strategies, CMA corresponds to a comparison be-
tween the two, simply on the basis of costs with a fi-
nal recommendation to use the cheaper one. How-
ever, it is rarely used.
“Cost-benefit” analysis (CBA) and “Cost-effec-
tiveness” analysis (CEA) correspond, respectively, to
the same monetary and non-monetary analysis of all
costs linked to a therapy or care strategy with a pre-
cise expected outcome. CEA shows the relationship
between all the resources used for a particular inter-
vention, and the health benefit achieved (28). Thus,
CEA can be used to assess the value of informal
care, and take into account the patient’s quality of care
(29).
“Cost-utility” analysis (CUA) addresses the cost of
a particular treatment or care strategy considering a
single important outcome, such as the patient’s “Qual-
ity of life” (30). CUA shows the relationship between
weights or utility weights (quality-adjusted life years or
QUALY) for a particular outcome and quality of life
(31). The use of generic scales allows comparisons be-
tween different diseases. However, specific scales
may help define an optimal level of care (9).
Pharmacoeconomics, a new area of health eco-
nomics, emerged in the late 70s from concerns about
the relative effectiveness and costs of different medi-
cations (32, 33). Pharmacoeconomics, in its strictest
sense, can be included among the previous types of
analysis, but it also encompasses the analysis of “cost
consequences”, which correspond to consumer pref-
erences and satisfaction with regard to outcomes and
costs of a specific treatment or health service (34). For
example, the cost-effectiveness of the new anti-de-
mentia drugs (such as acetylcholinesterase inhibitors)
includes not only the price of the drug, but also its abil-
ity to stabilize and improve patients’ (and caregivers’)
quality of life, and reduce caregiver burden (35). This
kind of analysis appears complex because it includes
data and costs that constantly vary such as delay in in-
stitutionalization and reduction in the number of
hours of informal care required by the patient, as
well as improvement in the patients’ and caregivers’
quality of life, and need to be compared with societal
trends and progress (1).
In the context of trade-off analysis, numerous eval-
uations have been performed to compare one strategy
of care to another, or to appreciate the impact of one
drug in comparison with another.
- Cost of Alzheimer’s disease and related de-
mentia in managed care
In the US, the high prevalence of dementia among
the oldest, coupled with total costs of up to $ 195,000
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for each case of AD (36), create very significant clin-
ical and financial incentives for managed care plans to
improve the care of members suffering from demen-
tia (37). Whatever the type of Health Care Organi-
zation (HMO), it appears that people diagnosed with
dementia have 1.5- to 1.9-fold higher health care
utilization and costs than enrolees without dementia
(p<0.001) (37, 38). This variability is related to dif-
ferent adjustments for co-morbidity, and the fact that
case managers differ significantly by site in how they
prioritize tasks, functions, and goals, viewing them-
selves along a continuum from a clinical approach to
one that emphasizes service management (39); the
higher costs among demented cases were always
linked to inpatient expenses (2/3 of the costs) (37,
38).
- How to reduce nursing home care and de-
mentia costs?
Institutionalization is the largest component of
cost, accounting for more than 2/3 of the cost for
people with severe dementia. Providing support to in-
formal carers, proposing substitutes for nursing homes
(day or residential care), and postponing the require-
ment for institutionalization through the use of newer
“anti-dementia” drugs can significantly lengthen the
time spent by demented individuals in their own
home (40-43). This not only has obvious quality of life
implications, but can also have a significant positive
impact on costs.
Assisted Care Facilities (ACF) combine housing
and supportive services for individuals who require as-
sistance with the tasks of daily living, but who do
not need the level of skilled nursing care provided in
nursing homes (NH) (44). Several recent studies have
shown that ACF costs were lower than NH costs, and
ACFs have been promoted as a substitute for nursing
home placement, when appropriate, for individuals
who can no longer live in their own home (26, 45-
47).
- Impact of new medications for Alzheimer’s
disease therapy
The lack of long-term data on resource use and
drug efficacy has led various authors to apply theo-
retical models to forecast the impact of cholinesterase
inhibitors on the course of AD. A decision analysis
model predicts a possible cost reduction of $ 9,250 for
each patient if treatment with tacrine is used from the
time of diagnosis (36). A “modelling approach” based
on disease progression suggests that the largest long-
term cost savings is obtained with treatment of mild
AD (MMSE > 20). However, if a patient’s life ex-
pectancy is expected to be less than 2 years, cost sav-
ings are increased by prioritizing patients with mod-
erate AD (20 > MMSE > 11) (48). In an “incremental
cost-effectiveness theoretical model” comparing the
impact of Donepezil vs no treatment on quality-ad-
justed life-years gained, drug costs appeared to be par-
tially offset. The model predicts that for mild AD,
the drug would pay for itself in terms of costs (47). But
the positive impact of these results is attenuated by the
application of a “Markov model”. By estimating the
5-year cost-effectiveness of adding Donepezil (5 mg/d)
to the usual care in the management of patients with
mild to moderate AD (10 < MMSE < 26) in Canada,
the overall cost savings reached CA$ 882 per patient
on Donepezil; patients not receiving Donepezil were
predicted to spend 2.21 years in non-severe demen-
tia, while treated AD patients were predicted to spend
2.41 years (49).
CONCLUSIONS
Economic analyses of geriatric syndromes are sel-
dom performed. However, demographic and epi-
demiological imperatives have led to significant interest
in the evaluation of AD-related costs. Dementia is a
chronic disease with far reaching implications. Ana-
lytical methods are still evolving and remain com-
plex. Unresolved methodological issues will need to be
addressed to further our understanding of long-term
economic consequences. At present, it appears clear
that diagnostic and drug costs are low compared to the
major cost of institutionalization. Thus, directing efforts
at early diagnosis, and delaying nursing home place-
ment are two key cost containment interventions; in
this respect, the need to support informal care should
not be underestimated
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